Fehr Stephanie, Wong Kingsley, Chin Richard, Williams Simon, de Klerk Nick, Forbes David, Krishnaraj Rahul, Christodoulou John, Downs Jenny, Leonard Helen
From Telethon Kids Institute (S.F., K.W., N.d.K., J.D., H.L.) and the School of Paediatrics and Child Health (D.F.), The University of Western Australia, Perth; Muir Maxwell Epilepsy Centre (R.C.), Child Life and Health, The University of Edinburgh, UK; Department of Neurology and Rehabilitation (S.W.), Princess Margaret Hospital, Perth; Western Sydney Genetics Program (R.K.), The Children's Hospital at Westmead, Sydney; Department of Paediatrics (J.C.), University of Melbourne; Murdoch Childrens Research Institute (J.C.), The Royal Children's Hospital, Melbourne; and School of Physiotherapy and Exercise Science (J.D.), Curtin University, Perth, Australia.
Neurology. 2016 Nov 22;87(21):2206-2213. doi: 10.1212/WNL.0000000000003352. Epub 2016 Oct 21.
To investigate seizure outcomes and their relationships to genotype and functional abilities in individuals with the cyclin-dependent kinase-like-5 (CDKL5) disorder.
Using the International CDKL5 Disorder Database, we identified 172 cases with a pathogenic CDKL5 mutation. We categorized individual mutations into 4 groups based on predicted structural and functional consequences. Negative binomial regression was used to model the linear association between current seizure rate and mutation group, current level of assistance required to walk 10 steps, and the highest level of expressive communication used to convey refusal or request.
All but 3 (169/172) patients had a history of epilepsy. The median age at seizure onset was 6 weeks (range 1 week-1.5 years) and the median seizure rate at ascertainment was 2 per day (range 0-20 per day). After adjusting for walking ability and confounders including use or otherwise of polytherapy, seizure rate was lower in those with truncating mutations between aa172 and aa781 compared to those with no functional protein (incidence rate ratio [IRR] 0.57; 95% confidence interval [CI] 0.35-0.93). Ability to walk and use of spoken language were associated with lower rates of current seizures when compared to those with the least ability after adjusting for genotype (walking: IRR 0.62; 95% CI 0.39-0.99, communication: IRR 0.48; 95% CI 0.23-1.02). At a median age at questionnaire completion of 5 years, those previously treated with corticosteroids had more frequent seizures than those who have never been treated, whether or not there was a history of infantile spasms.
Epilepsy is pervasive but not mandatory for the CDKL5 disorder. Genotype and functional abilities were related to seizure frequency, which appears refractory to antiepileptic drugs.
研究细胞周期蛋白依赖性激酶样5(CDKL5)障碍患者的癫痫发作结局及其与基因型和功能能力的关系。
利用国际CDKL5障碍数据库,我们识别出172例具有致病性CDKL5突变的病例。我们根据预测的结构和功能后果将个体突变分为4组。使用负二项回归来模拟当前癫痫发作率与突变组、行走10步所需的当前辅助水平以及用于表达拒绝或请求的最高表达性沟通水平之间的线性关联。
除3例(169/172)患者外,所有患者都有癫痫病史。癫痫发作的中位年龄为6周(范围1周 - 1.5岁),确诊时的中位癫痫发作率为每天2次(范围0 - 20次/天)。在调整行走能力和混杂因素(包括是否使用联合治疗)后,与没有功能性蛋白的患者相比,在第172位氨基酸至第781位氨基酸之间发生截短突变的患者癫痫发作率较低(发病率比[IRR] 0.57;95%置信区间[CI] 0.35 - 0.93)。在调整基因型后,与能力最差的患者相比,行走能力和口语使用能力与当前癫痫发作率较低相关(行走:IRR 0.62;95% CI 0.39 - 0.99,沟通:IRR 0.48;95% CI 0.23 - 1.02)。在问卷完成时的中位年龄为5岁时,无论是否有婴儿痉挛病史,之前接受过皮质类固醇治疗的患者癫痫发作比从未接受过治疗的患者更频繁。
癫痫在CDKL5障碍中普遍存在但并非必然发生。基因型和功能能力与癫痫发作频率相关,癫痫发作似乎对抗癫痫药物难治。